Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium
Belite Bio (NASDAQ: BLTE), a clinical-stage drug development company focused on degenerative retinal diseases, will participate in a fireside chat at the Piper Sandler Virtual Ophthalmology Investor Symposium on July 9, 2026 at 12:30 pm ET.
Rhea-AI Summary
Belite Bio (NASDAQ: BLTE), a clinical-stage drug development company focused on degenerative retinal diseases, will participate in a fireside chat at the Piper Sandler Virtual Ophthalmology Investor Symposium on July 9, 2026 at 12:30 pm ET.
The live webcast and 90-day replay will be available under “Events” in the investor relations section of the Belite Bio website.
Positive
- None.
Negative
- None.
Details
Market move: BLTE +5.04% in the Jul 6 session. ophthalmology symposium participation
On Jul 6, the day this news came out, BLTE closed 5.04% above the previous close. Our momentum scanner recorded 4 alerts for this stock that day.
Data tracked by StockTitan Argus for the Jul 6 session.
Key Figures
- Event date
- July 9, 2026
- Piper Sandler Virtual Ophthalmology Investor Symposium
- Event time
- 12:30 pm ET
- Fireside chat start time
- Replay duration
- 90 days
- Webcast replay availability after presentation
Historical Context
-
Completed rolling NDA submission to FDA for tinlarebant in STGD1.
-
Announced fireside chat at Goldman Sachs Global Healthcare Conference.
-
Reported Q1 2026 results and progress on NDA and late-stage trials.
-
Received Swiss orphan drug status for tinlarebant in Stargardt disease.
-
Announced oral presentation of Phase 3 DRAGON topline results at Retina China.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, July 06, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the Company will participate in a fireside chat at the Piper Sandler Virtual Ophthalmology Investor Symposium on Thursday, July 9, 2026, at 12:30 pm ET.
Webcast Link Instructions
A webcast of the presentation can be accessed under "Events" in the investor relations section of the Belite Bio website at: https://investors.belitebio.com/presentations-events/events. The replay will be archived for 90 days following the presentation date.
About Belite Bio
Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, such as Stargardt disease type 1 (STGD1) and geographic atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite Bio’s lead candidate, tinlarebant, is an oral therapy intended to reduce the accumulation of bisretinoid toxins in the eye. The Company has completed a Phase 3 trial (DRAGON) in adolescent and adult subjects with STGD1, which met its primary endpoint, and the drug is currently being evaluated in a Phase 2/3 trial (DRAGON II) in adolescent and adult subjects with STGD1 and a Phase 3 trial (PHOENIX) in subjects with GA. For more information, follow us on X, Instagram, LinkedIn, and Facebook, or visit us at www.belitebio.com.
Media and Investor Relations Contacts:
Jennifer Wu / ir@belitebio.com
Argot Partners / belite@argotpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.